In this panel, experts in pharmacy, policy and harm reduction will help answer the question “Is over-the-counter naloxone enough to stop the overdose crisis?” They will discuss what intranasal naloxone’s OTC status does and does not do, as well as important next steps for regulators and policymakers working to curb overdose deaths in their communities and across the country.